Illumina Inc., a global leader in DNA sequencing and array-based technologies, hosted the Illumina Multiomics Summit India 2026 in collaboration with Premas Life Sciences. 

The two-city event, held in New Delhi on May 6 and Bengaluru on May 8, brought together more than 200 genomics experts, clinicians, pathologists, scientists, and translational researchers to discuss the growing role of multi-omics in life sciences and precision healthcare.

The summit focused on the transition from single-omics research to integrated multi-omics approaches, combining genomics, transcriptomics, epigenomics, and proteomics to create a deeper understanding of disease biology. Experts noted that these integrated datasets can improve translational research and support future clinical applications through more data-driven healthcare strategies.

The discussions also highlighted the importance of multi-omics research in addressing India’s healthcare challenges. With a population of nearly 1.4 billion people and significant genetic and cultural diversity, India presents major opportunities for large-scale biomedical research. At the same time, the country continues to face a high burden of chronic and rare diseases, including diabetes, cardiovascular disorders, cancer, and rare genetic conditions, increasing the need for predictive and personalized treatment approaches.

 “Multi-omics is reshaping our understanding of biology by moving from isolated data layers to a more integrated view of disease - an approach that is increasingly becoming important for advancing precision health and is beginning to inform clinical space, particularly in oncology,” said Suchita Dayanand, Country Head – India (Commercial) at Illumina Inc..